Febrile Neutropenia - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides an overview of the Febrile Neutropenia (Hematological Disorders) pipeline landscape.

Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of chemotherapy when it is myelosuppressive (suppresses the bone marrow from producing blood cells). Symptoms include fever, flu-like symptoms, shaking chills, severe night sweats, nausea and vomiting, especially with fever, tenderness, redness, swelling, pain or discharge at the site of a catheter and headache or neck stiffness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Febrile Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Febrile Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Febrile Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 1, 2, 2, 1 and 3 respectively for Febrile Neutropenia.

Febrile Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Febrile Neutropenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Febrile Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Febrile Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Febrile Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Febrile Neutropenia (Hematological Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Febrile Neutropenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Febrile Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Febrile Neutropenia Overview 7
Therapeutics Development 8
Pipeline Products for Febrile Neutropenia - Overview 8
Febrile Neutropenia - Therapeutics under Development by Companies 9
Febrile Neutropenia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Febrile Neutropenia - Products under Development by Companies 15
Febrile Neutropenia - Companies Involved in Therapeutics Development 16
Apotex Inc. 16
BeyondSpring Pharmaceuticals, Inc. 17
Biogenomics Limited 18
Coherus BioSciences, Inc. 19
Dr. Reddy's Laboratories Limited 20
Richter Gedeon Nyrt. 21
Sandoz International GmbH 22
Therapeutic Proteins International, LLC 23
USV Pvt Ltd 24
Febrile Neutropenia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
EC-18 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
filgrastim - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
filgrastim - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
filgrastim - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
pegfilgrastim - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
pegfilgrastim - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
pegfilgrastim - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
pegfilgrastim - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
pegfilgrastim - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
pegfilgrastim - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
pegfilgrastim - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
pegfilgrastim - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
pegfilgrastim - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
pegfilgrastim - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
plinabulin - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Febrile Neutropenia - Dormant Projects 53
Febrile Neutropenia - Product Development Milestones 54
Featured News & Press Releases 54
Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study 54
Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 55
Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study 55
Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701 56
Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program 56
Dec 08, 2015: EMA started the evaluation of Richter's marketing authorisation application for biosimilar pegfilgrastim 57
Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA 57
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

Number of Products under Development for Febrile Neutropenia, H2 2016 8
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Comparative Analysis by Unknown Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Febrile Neutropenia - Pipeline by Apotex Inc., H2 2016 16
Febrile Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016 17
Febrile Neutropenia - Pipeline by Biogenomics Limited, H2 2016 18
Febrile Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016 19
Febrile Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 20
Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016 21
Febrile Neutropenia - Pipeline by Sandoz International GmbH, H2 2016 22
Febrile Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016 23
Febrile Neutropenia - Pipeline by USV Pvt Ltd, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Febrile Neutropenia - Dormant Projects, H2 2016 53